Target intelligence / Profile preview

Dynein axonemal heavy chain 2 (DNAH2)

Target
DNAH2
Molecular classification
Motor protein, AAA+ ATPase, Axonemal dynein family
01

Overview

Dynein axonemal heavy chain 2 is a member of the axonemal dynein family of motor proteins, encoded by the DNAH2 gene in humans[2]. It functions as a motor protein whose ATPase activity drives movement along microtubules, generating force for the sliding of microtubules within cilia and flagella. This movement is essential for the proper motility of these organelles, thereby supporting processes such as mucociliary clearance in the airways and sperm motility in reproduction[3][6][5]. Axonemal dyneins form multimeric complexes; DNAH2 is a key heavy chain component, interacting with intermediate and light chains to produce highly regulated bending motions crucial for cellular and organismal physiological functions[5][6][1]. Mutations in DNAH2 have been implicated in primary ciliary dyskinesia and related diseases, presenting with respiratory disorders and reproductive issues[2]. Axonemal dyneins—and dynein axonemal heavy chain 2 specifically—are not considered druggable targets; rather, their dysfunction is clinically relevant in genetic disease diagnostics.

Other names
DNAH2Dynein, axonemal, heavy chain 2
02

Mechanism of action

Not applicable; no drugs currently act on this target. General motor function is ATP hydrolysis-driven microtubule movement

03

Biological functions

Ciliary motility/flagellar motility (drives movement of cilia and flagella)ATP-dependent microtubule slidingForce generation and mechanochemical transductionRegulation of beat frequency and waveform in motile cilia
04

Disease associations

Primary ciliary dyskinesia (mutation in DNAH2 can lead to ciliary movement disorders)Male infertility due to defective sperm flagella (associated with immotile sperm syndrome)Kartagener syndrome (subset of ciliary dyskinesias)
05

Safety considerations

Loss-of-function mutations impair ciliary function leading to respiratory diseases, infertility, and situs inversus.No safety concerns from therapeutic modulation documented.
06

Biomarkers

DNAH2 mutations are used as genetic markers for ciliary dyskinesia and certain cases of male infertility

Beyond the preview

Go deeper on Dynein axonemal heavy chain 2 (DNAH2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynein axonemal heavy chain 2 (DNAH2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call